Loading...
Loading...
BLTE| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 11.0M |
| Operating I/L | -11.0M |
| Other Income/Expense | 0.0M |
| Interest Income | 0.0M |
| Pretax | -10.9M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -10.9M |
Belite Bio, Inc is a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics for age-related macular degeneration and liver diseases. Its lead product candidate, LBS-008, is an oral once-a-day treatment in phase 3 clinical trial, targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy for liver diseases, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, currently in preclinical development.
